Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Apr:88:105558.
doi: 10.1016/j.tiv.2023.105558. Epub 2023 Jan 18.

Pharmacological PI3K inhibition in head and neck squamous cell carcinoma: A systematic review

Affiliations

Pharmacological PI3K inhibition in head and neck squamous cell carcinoma: A systematic review

L B Alves et al. Toxicol In Vitro. 2023 Apr.

Abstract

Background: This systematic review aimed to investigate the in vitro and in vivo effects of phosphatidylinositol-3-kinase (PI3K) inhibitors on head and neck squamous cell carcinoma (HNSCC). Considering the role of PI3K and its downstream effectors in cell proliferation, invasion, and survival, it is reasonable to expect that treatment with PI3K inhibitors could control HNSCC onset and progression. Thus, the research question for our review was whether pharmacological inhibition of PI3K affects HNSCC progression.

Methods: In vitro and in vivo studies were selected from six databases. We collected data regarding cell viability, apoptosis, and the regulation of protein expression levels from in vitro studies. For the in vivo studies, we analyzed the reduction in tumor size or gene and protein expression.

Results: The included studies showed reduced cell proliferation and apoptosis after treatment with PI3K inhibitors. PI3K inhibitors in combination with other drugs had an enhanced anticancer effects compared to those of single-drug treatments.

Conclusions: The results support the potential of PI3K inhibitors as candidates for clinical trials in HNSCC.

Keywords: Head and neck carcinoma; PI3K inhibitors; Pharmacological effects; Systematic review.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest The authors have no conflicts of interest to declare.

Publication types

MeSH terms

Substances

LinkOut - more resources